Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.

Marino ClavioElena CrisàMaurizio MiglinoFabio GuoloManuela CeccarelliFlavia SalviBernardino AllioneDario FerreroEnrico BalleariCarlo FinelliAntonella PoloniCarmine SelleriPaolo DaniseDaniela CilloniAnna Angela Di TucciGianni CamettiRoberto FreiloneRenato FaninCatia BigazziRenato ZambelloMonica CrugnolaEsther N OlivaRiccardo CenturioniFrancesco AlesianiMassimo CatariniAndrea CastelliAntonio AbbadessaSilvana F CapalboPellegrino MustoEmanuele AngelucciValeria Santini

Published in: Cancer (2021)

Real-life data confirm that this prognostic scoring system for MDS patients failing a hypomethylating agent seems to be a useful tool for optimal prognostic stratification and for choosing a second-line treatment after AZA discontinuation.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
clinical practice
prognostic factors
peritoneal dialysis
machine learning
patient reported outcomes
electronic health record
free survival